Research
Hormonal
Semaglutide improved hemoglobin A1c levels and reduced glycemic variability without increasing hypoglycemia.
Semaglutide may enhance glycemic control in type 1 diabetes patients.
StrongSupportsmedium confidence
Despite less insulin, hemoglobin A1c improved, with reduced glycemic variability and no increase in hypoglycemia.
Why this rating
The findings are based on a case study with clear outcomes.
Source
Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
Lisa M. Raven et al. · JCEM Case Reports · 2022
DOI 10.1210/jcemcr/luac017
case_studyCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →